Insider Selling: BioLife Solutions (NASDAQ:BLFS) Insider Sells 714 Shares of Stock

Key Points

• Insider Sarah Aebersold sold 714 shares of BioLife Solutions stock on September 15th for a total of $18,285.54, reducing her ownership by 0.91% to 77,357 shares valued at approximately $1.98 million.
• BioLife Solutions reported a significant earnings per share miss of ($0.33) for the last quarter, compared to Consensus estimates of ($0.02), although it achieved better-than-expected revenue of $25.42 million.
• Despite a challenging earnings report, analysts have varied ratings on the stock, with Zacks upgrading BioLife Solutions to a "strong-buy" and a consensus target price of $31.29.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 714 shares of BioLife Solutions stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $25.61, for a total value of $18,285.54. Following the completion of the sale, the insider directly owned 77,357 shares in the company, valued at approximately $1,981,112.77. This represents a 0.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Thursday, September 11th, Sarah Aebersold sold 233 shares of BioLife Solutions stock. The shares were sold at an average price of $26.83, for a total value of $6,251.39.
• On Tuesday, August 26th, Sarah Aebersold sold 219 shares of BioLife Solutions stock. The shares were sold at an average price of $25.44, for a total value of $5,571.36.
• On Monday, July 7th, Sarah Aebersold sold 198 shares of BioLife Solutions stock. The shares were sold at an average price of $22.27, for a total value of $4,409.46.

BioLife Solutions Price Performance

BLFS stock traded down $0.71 during mid-day trading on Friday, reaching $25.57. The company had a trading volume of 562,596 shares, compared to its average volume of 390,836. The stock has a 50 day simple moving average of $23.83 and a two-hundred day simple moving average of $23.31. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -213.07 and a beta of 1.78. BioLife Solutions, Inc. has a 52 week low of $19.10 and a 52 week high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). The company had revenue of $25.42 million during the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. On average, equities analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Analyst Upgrades and Downgrades

BLFS has been the subject of several research analyst reports. Zacks Research upgraded BioLife Solutions to a "strong-buy" rating in a research note on Monday, August 11th. HC Wainwright reiterated a "buy" rating and set a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Finally, Stephens initiated coverage on BioLife Solutions in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $31.29.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLFS. Deutsche Bank AG raised its holdings in BioLife Solutions by 49.8% in the 4th quarter. Deutsche Bank AG now owns 31,171 shares of the medical equipment provider's stock valued at $809,000 after acquiring an additional 10,368 shares in the last quarter. Gotham Asset Management LLC raised its holdings in BioLife Solutions by 11.5% in the 4th quarter. Gotham Asset Management LLC now owns 13,800 shares of the medical equipment provider's stock valued at $358,000 after acquiring an additional 1,426 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in BioLife Solutions by 5.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,508 shares of the medical equipment provider's stock valued at $532,000 after acquiring an additional 1,047 shares in the last quarter. ProShare Advisors LLC acquired a new position in BioLife Solutions in the 4th quarter valued at $282,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions in the 4th quarter valued at $31,000. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.